OncoMatch/Clinical Trials/NCT02297217
Chemoradiotherapy for Advanced Esophageal Cancer
Is NCT02297217 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Carboplatin and Taxol (paclitaxel) for esophageal cancer.
Treatment: Carboplatin and Taxol (paclitaxel) — This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Previous radiotherapy delivered to the chest.
Cannot have received: cytotoxic chemotherapy
Previous chemotherapy for esophageal cancer
Lab requirements
Blood counts
Hemoglobin > 100g/L; Platelet count > 100x10E9/L; Absolute neutrophil count > 1.5x10E9/L
Kidney function
Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula
Liver function
AST and ALT ≤ 2.5x ULN (≤ 5 if liver metastases); total bilirubin ≤ 1.5x ULN
Hematological function as defined by the following laboratory parameters: Hemoglobin > 100g/L; Platelet count > 100x10E9/L; Absolute neutrophil count > 1.5x10E9/L. Renal function to undergo chemotherapy as defined by the following laboratory parameters: AST and ALT ≤ 2.5x ULN (≤ 5 if liver metastases); total bilirubin ≤ 1.5x ULN; Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify